11.3 Antimicrobial Resistance Genotyping

11.3 Antimicrobial Resistance Genotyping

Quick Summary: Antimicrobial resistance (AMR) genotyping bypasses the 24- to 48-hour incubation lag of conventional phenotypic broth microdilution by directly amplifying and detecting the specific genes, single-nucleotide polymorphisms (SNPs), or mobile genetic elements that confer drug resistance. Key clinical testing paradigms encompass methicillin resistance in staphylococci (mecA, mecC), vancomycin resistance in enterococci (vanA, vanB, vanC), Gram-negative $\beta$-lactamases (Ambler Classes A–D including blaKPC, blaNDM, blaOXA-48, blaCTX-M), plasmid-mediated colistin resistance (mcr-1), and multi-drug resistant Mycobacterium tuberculosis (rpoB, katG, inhA). Understanding the molecular mechanisms of target modification, enzymatic hydrolysis, and genetic mobilization is essential for accurate clinical interpretation and ASCP MB exam success.

---

1. Gram-Positive Resistance Genotyping

+---------------------------------------------------------------------------------------------------------+
|                               GRAM-POSITIVE RESISTANCE GENOTYPES & MECHANISMS                           |
+---------------------+-------------------+-----------------------------------+---------------------------+
| Organism / Drug     | Resistance Gene(s)| Biochemical Mechanism of Action   | Clinical & Diagnostic     |
| Class               |                   |                                   | Considerations            |
+---------------------+-------------------+-----------------------------------+---------------------------+
| ***S. aureus*** /   | ***mecA*** /      | Encodes altered **PBP2a (PBP2')** | Carried on mobile         |
| Staphylococci       | ***mecC***        | transpeptidase; exceptionally low | **SCC*mec*** cassette.    |
| (Methicillin /      |                   | affinity for all $\beta$-lactams   | *SCCmec-orfX* junction PCR|
| Oxacillin / Cefoxitin)                  | except 5th-gen cephalosporins.    | used for nasal screening. |
+---------------------+-------------------+-----------------------------------+---------------------------+
| ***Enterococcus***  | ***vanA***        | Reprograms peptidoglycan precursor| **High-level inducible**  |
| species             | (Tn1546)          | from D-Ala-D-Ala to **D-Ala-D-Lac**;| resistance to **both**   |
| (Vancomycin /       |                   | 1,000-fold reduced vancomycin bind| vancomycin & teicoplanin. |
| Glycopeptides)      +-------------------+-----------------------------------+---------------------------+
|                     | ***vanB***        | Synthesizes **D-Ala-D-Lac**;      | Inducible resistance to   |
|                     |                   | activated by vancomycin only      | vancomycin; susceptible to|
|                     |                   |                                   | teicoplanin *in vitro*.   |
|                     +-------------------+-----------------------------------+---------------------------+
|                     | ***vanC1*** /     | Synthesizes **D-Ala-D-Ser**       | **Intrinsic low-level**   |
|                     | ***vanC2/3***     | precursors (low-affinity binding) | non-transferable resistance|
|                     |                   |                                   | in *E. gallinarum/casseli*|
+---------------------+-------------------+-----------------------------------+---------------------------+

Methicillin Resistance in Staphylococcus aureus (MRSA)

• The mecA / mecC Mechanism: Methicillin resistance is mediated by acquisition of the mecA gene (or its divergent homologue mecC), located on the mobile genomic island Staphylococcal Cassette Chromosome mec (SCCmec). The gene encodes an alternative $78\text{ kDa}$ penicillin-binding protein, PBP2a (or PBP2'), whose active-site transpeptidase domain possesses exceptionally low binding affinity for virtually all $\beta$-lactam antibiotics (penicillins, cephalosporins, carbapenems), allowing peptidoglycan cross-linking to proceed unimpeded.
• SCCmec-orfX Junction PCR for MRSA Nasal Surveillance:
  • Rapid MRSA nasal screening assays utilize primers targeting the junction between the right extremity of the integrated SCCmec cassette and the conserved chromosomal integration site (orfX) of S. aureus.
  • The "Empty Cassette" Diagnostic Pitfall: Occasionally, a methicillin-susceptible S. aureus (MSSA) strain excises the mecA structural gene but retains a remnant fragment of the SCCmec right extremity inserted in orfX. A junction-only PCR assay will yield a false-positive MRSA result. Advanced molecular assays avoid this by utilizing dual-target triplex PCR that simultaneously confirms the SCCmec-orfX junction AND the presence of the structural mecA/mecC and S. aureus-specific nuc or spa genes.

                           MRSA SCCmec-orfX JUNCTION & EMPTY CASSETTE
                           
   True MRSA Cassette:
   ---[ S. aureus Chromosome (orfX) ]===[ SCCmec Right Extremity ]---[ mecA Gene ]---> (TRUE POSITIVE)
                                        |--- Junction PCR Primer Target ---|
   
   "Empty Cassette" MSSA Variant:
   ---[ S. aureus Chromosome (orfX) ]===[ Remnant SCCmec Extremity ]-----------------> (FALSE POSITIVE MRSA!)
                                        |--- Junction PCR Still Amplifies! ---|

Vancomycin Resistance in Enterococcus (VRE)

• Peptidoglycan Target Remodeling: Vancomycin binds with high affinity to the terminal D-Alanyl-D-Alanine (D-Ala-D-Ala) dipeptide of cell-wall lipid II precursors via 5 hydrogen bonds, physically blocking transglycosylase and transpeptidase enzymes from building the peptidoglycan wall.
• The vanA & vanB Operons: VRE strains carry a multi-gene regulatory operon (vanR-vanS-vanH-vanA-vanX-vanY-vanZ) that senses glycopeptides and synthesizes modified D-Alanyl-D-Lactate (D-Ala-D-Lac) termini. Replacing the terminal amide hydrogen with an ester oxygen eliminates a critical hydrogen bond and introduces electrostatic repulsion, reducing vancomycin binding affinity by 1,000-fold.
• Clinical Distinction of vanC: Strains of Enterococcus gallinarum (vanC1) and Enterococcus casseliflavus (vanC2/vanC3) possess intrinsic, chromosomal, non-transferable resistance via D-Alanyl-D-Serine (D-Ala-D-Ser) synthesis. These organisms exhibit low-level resistance (vancomycin $\text{MIC } 4–32;\mu\text{g/mL}$) and do not represent an infection control outbreak emergency like plasmid-borne vanA/vanB VRE.

---

2. Gram-Negative Resistance & $\beta$-Lactamase Classification

Gram-negative $\beta$-lactamases hydrolyze the four-membered $\beta$-lactam ring, rendering antibiotics inactive. They are classified structurally via the Ambler Molecular Classification based on active-site amino acid homology.

+---------------------------------------------------------------------------------------------------------+
|                                AMBLER MOLECULAR CLASSIFICATION OF BETA-LACTAMASES                       |
+--------+-------------------+-----------------------+-------------------+--------------------------------+
| Ambler | Active Site       | Representative        | Hydrolysis        | Inhibitor Profile              |
| Class  | Catalytic Group   | Resistance Genes      | Substrate Spectrum|                                |
+--------+-------------------+-----------------------+-------------------+--------------------------------+
| **A**  | **Active-Site**   | ***bla*TEM**,         | Penicillins,      | **Inhibited by:** Clavulanic   |
|        | **Serine**        | ***bla*SHV**,         | early/extended    | acid, Tazobactam, Avibactam,   |
|        |                   | ***bla*CTX-M** (ESBLs)| cephalosporins,   | Vaborbactam.                   |
|        |                   | ***bla*KPC**          | & carbapenems     | (*bla*KPC hydrolyzes           |
|        |                   | (Carbapenemase)       | (*bla*KPC only).  | carbapenems).                  |
+--------+-------------------+-----------------------+-------------------+--------------------------------+
| **B**  | **Divalent Zinc** | ***bla*NDM** (New     | **ALL** $\beta$-lactams| **NOT inhibited by:** Avibactam|
|        | **Cofactor**      | Delhi), ***bla*VIM**, | and carbapenems   | or Clavulanic acid.            |
|        | **(Metallo-MBL)** | ***bla*IMP**          | **EXCEPT**        | **Inhibited by:** EDTA &       |
|        |                   |                       | **Aztreonam**.    | divalent metal chelators.      |
+--------+-------------------+-----------------------+-------------------+--------------------------------+
| **C**  | **Active-Site**   | ***bla*AmpC**,        | Penicillins,      | **Resistant to:** Clavulanate  |
|        | **Serine**        | ***bla*CMY**,         | 1st-3rd gen       | and Tazobactam.                |
|        | (Cephalosporinase)| ***bla*FOX**,         | cephalosporins,   | Susceptible to: **Cefepime**   |
|        |                   | ***bla*DHA**          | cephamycins (fox).| and Carbapenems.               |
+--------+-------------------+-----------------------+-------------------+--------------------------------+
| **D**  | **Active-Site**   | ***bla*OXA-48-like**, | Oxacillin,        | **Poorly inhibited** by        |
|        | **Serine**        | ***bla*OXA-23**,      | penicillins, and  | clavulanate;                   |
|        | (Oxacillinases)   | ***bla*OXA-24/40**    | variable low-level| variable inhibition by         |
|        |                   |                       | carbapenems.      | Avibactam.                     |
+--------+-------------------+-----------------------+-------------------+--------------------------------+

Key Gram-Negative Resistance Determinants

1. Extended-Spectrum $\beta$-Lactamases (ESBLs): Predominantly blaCTX-M variants (such as blaCTX-M-14 and blaCTX-M-15). Hydrolyze third-generation cephalosporins (ceftriaxone, ceftazidime, cefotaxime) and monobactams (aztreonam), but are inhibited by $\beta$-lactamase inhibitors (clavulanate, tazobactam).
2. Klebsiella pneumoniae Carbapenemase (blaKPC): Ambler Class A serine carbapenemase carried on Tn4401 transposons. Hydrolyzes all penicillins, cephalosporins, and carbapenems (ertapenem, imipenem, meropenem). Inhibited by novel non-$\beta$-lactam $\beta$-lactamase inhibitors like avibactam and vaborbactam.
3. Metallo-$\beta$-Lactamases (MBLs - blaNDM, blaVIM, blaIMP): Ambler Class B enzymes requiring divalent zinc ($\text{Zn}^{2+}$) ions in their active site to coordinate and hydrolyze the $\beta$-lactam carbonyl bond.
   • High-Yield ASCP MB Rule: MBLs hydrolyze all $\beta$-lactams and carbapenems EXCEPT monobactams (aztreonam).
   • They are refractory to all classic and modern $\beta$-lactamase inhibitors (clavulanate, tazobactam, avibactam, vaborbactam, relebactam). They are inhibited in vitro only by metal-chelating agents such as EDTA or dipicolinic acid.
4. Plasmid-Mediated Colistin Resistance (mcr-1 to mcr-10):
   • Colistin (polymyxin E) is a positively charged cationic peptide that binds electrostatically to the negatively charged phosphate groups of Lipid A in Gram-negative lipopolysaccharide (LPS).
   • The mcr-1 gene encodes a membrane-bound phosphoethanolamine transferase that transfers a phosphoethanolamine moiety onto Lipid A. This neutralizes the negative surface charge of LPS, preventing colistin binding and conferring resistance.

---

3. Mycobacterial & Viral Drug Resistance Genotyping

+---------------------------------------------------------------------------------------------------------+
|                               MYCOBACTERIAL & VIRAL RESISTANCE GENOTYPES                                |
+---------------------+-------------------+-----------------------------------+---------------------------+
| Pathogen            | Resistance Target | Molecular Mechanism / Codon Change| Clinical Implication      |
+---------------------+-------------------+-----------------------------------+---------------------------+
| ***Mycobacterium*** | ***rpoB***        | Mutations in **81-bp RRDR**       | **Rifampin resistance;**  |
| ***tuberculosis***  | (RNA Pol $\beta$) | (Codons 507–533; e.g., **S531L**) | surrogate for **MDR-TB**. |
|                     +-------------------+-----------------------------------+---------------------------+
|                     | ***katG***        | Catalase-peroxidase mutation      | **High-level Isoniazid**  |
|                     |                   | (e.g., **S315T**)                 | (INH) resistance.         |
|                     +-------------------+-----------------------------------+---------------------------+
|                     | ***inhA***        | Promoter mutation (e.g., **C-15T**)| **Low-level INH** +       |
|                     |                   | upregulating enoyl-ACP reductase  | **Ethionamide** cross-res.|
|                     +-------------------+-----------------------------------+---------------------------+
|                     | ***gyrA / gyrB*** | Quinolone resistance region (QRDR)| Fluoroquinolone resistance|
+---------------------+-------------------+-----------------------------------+---------------------------+
| **HIV-1**           | **Reverse Trans-**| **M184V** (NRTI resistance)       | High-level 3TC/FTC resist.|
|                     | **criptase**      | **K103N** (NNRTI resistance)      | Efavirenz/Nevirapine resist|
|                     +-------------------+-----------------------------------+---------------------------+
|                     | **Integrase**     | **Q148H/R/K**, **N155H**          | INSTI resistance          |
+---------------------+-------------------+-----------------------------------+---------------------------+
| **CMV**             | ***UL97*** kinase | **M460V/I**, **H520Q**, **C592G** | Ganciclovir resistance;   |
|                     |                   | (Prevents monophosphorylation)    | Foscarnet remains active. |
|                     +-------------------+-----------------------------------+---------------------------+
|                     | ***UL54*** DNA pol| DNA polymerase catalytic mutations| **Cross-resistance to**   |
|                     |                   |                                   | **ganciclovir & foscarnet**|
+---------------------+-------------------+-----------------------------------+---------------------------+

Mycobacterium tuberculosis (MDR-TB and XDR-TB)

• Multidrug-Resistant Tuberculosis (MDR-TB): Defined as M. tuberculosis strains resistant to at least the two primary first-line antitubercular drugs: Rifampin (RIF) and Isoniazid (INH).
• Extensively Drug-Resistant Tuberculosis (XDR-TB): Defined as MDR-TB plus resistance to any fluoroquinolone (e.g., levofloxacin, moxifloxacin) and at least one additional Group A drug (e.g., bedaquiline or linezolid).
• Molecular Diagnostic Targets:
  • rpoB (Rifampin): $>95%$ of all rifampin-resistant strains harbor mutations within an 81-base pair Rifampin Resistance Determining Region (RRDR) (codons 507 to 533) of the RNA polymerase $\beta$-subunit. Because $>90%$ of rifampin-resistant isolates are also resistant to isoniazid, detection of an rpoB mutation serves as an immediate molecular surrogate for MDR-TB.
  • katG (Isoniazid - High Level): Isoniazid is a prodrug requiring activation by the mycobacterial catalase-peroxidase enzyme encoded by katG. The Ser315Thr (S315T) missense mutation impairs prodrug activation, causing high-level INH resistance.
  • inhA Promoter (Isoniazid - Low Level & Cross-Resistance): Mutations in the ribosome-binding/promoter region of inhA (e.g., C-15T) cause overexpression of the target enoyl-ACP reductase enzyme. This confers low-level INH resistance and concurrent cross-resistance to the second-line drug ethionamide.

---

4. Genotype-to-Phenotype Discrepancies & Limitations

While molecular resistance testing provides same-day results, technologists must understand the biological causes of genotype-to-phenotype discrepancies:

1. Unexpressed or Downregulated Genes: Detection of a resistance gene (e.g., blaTEM or ampC) does not guarantee high-level phenotypic resistance if promoter mutations prevent robust transcription or if the gene is a non-functional pseudogene.
2. Alternative Resistance Mechanisms: The absence of a specific target gene (e.g., lack of blaKPC) does not guarantee susceptibility; carbapenem resistance can result from outer membrane porin loss (e.g., ompK35/ompK36 deletion) coupled with hyperproduced AmpC or ESBL enzymes.
3. Novel Uncharacterized Mutations: Targeted assays only detect known, probed mutations. Novel single-nucleotide variants in enzyme active sites will be missed unless full-gene Next-Generation Sequencing (NGS) is employed.